Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer.
about
Cell polarity signaling in the plasticity of cancer cell invasivenessTargeting protein kinase C subtypes in pancreatic cancerProtein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung AdenocarcinomaA mixed-methods feasibility trial of protein kinase C iota inhibition with auranofin in asymptomatic ovarian cancer patients.Atypical PKC-iota Controls Stem Cell Expansion via Regulation of the Notch Pathway.The chromosome 3q26 OncCassette: A multigenic driver of human cancer.Targeting oncogenic protein kinase Cι for treatment of mutant KRAS LADC.A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer.Atypical protein kinase Cι as a human oncogene and therapeutic target.The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials.A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion.Protein kinase C in cancer: The top five unanswered questions.Oncogenic PKCι decides tumor-initiating cell fate.
P2860
Q26766248-AD8F7567-B979-4E31-B692-50D7B9D3F69DQ28081364-EC7BD10D-D4C3-4E2F-B17D-97FA9F7CBD8AQ28115044-69576303-79FB-4B41-927D-57EBBB527F17Q35954798-B3AACAF6-4005-4D76-AE76-7E912038860BQ36290989-33E460A6-2C3C-47FB-80FE-CC9C34374561Q36510237-5EC3DA04-0C5B-4E40-BFE9-F65540F1BF33Q37673912-C27A535E-B564-4C1B-885F-6F89AE90F1F5Q37724940-86408AFB-7F5A-4F1E-BA0E-F693C4D4F72BQ38162656-1F143242-D96B-4023-A466-D29772764A45Q38263351-3FA011B5-1A37-43A6-A18B-D9BFD2A03291Q38882024-E02E9BB2-4EBC-4782-A305-1CA9B9CF2B78Q39098659-288FA323-37A1-4DB1-AAC8-F3891ED23592Q41113458-7CDE91A2-701B-4610-B72F-8915C25A3AB0
P2860
Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Phase I dose escalation study ...... cancer, and pancreatic cancer.
@en
Phase I dose escalation study ...... cancer, and pancreatic cancer.
@nl
type
label
Phase I dose escalation study ...... cancer, and pancreatic cancer.
@en
Phase I dose escalation study ...... cancer, and pancreatic cancer.
@nl
prefLabel
Phase I dose escalation study ...... cancer, and pancreatic cancer.
@en
Phase I dose escalation study ...... cancer, and pancreatic cancer.
@nl
P2093
P2860
P1433
P1476
Phase I dose escalation study ...... cancer, and pancreatic cancer
@en
P2093
Alan P Fields
Alex A Adjei
Aminah Jatoi
Charles Erlichman
Julian R Molina
Yingwei Qi
P2860
P304
P356
10.1097/CAD.0000000000000009
P577
2013-11-01T00:00:00Z